Rhythm Pharmaceuticals, Inc. - Common Stock — 재무제표 (NASDAQ:RYTM) | MetaTrader

전체 차트 열기 Full chart

Financials

개요 성명 통계

총자산 187.07 M329.52 M382.48 M332.75 M392.27 M480.2 M 총 부채 20.55 M45.37 M118.22 M162.99 M227.72 M210.17 M 자본금 총액 166.53 M284.15 M264.26 M169.76 M21.73 M139.07 M 총 부채 및 주주자본 187.07 M329.52 M382.48 M332.75 M392.27 M480.2 M 총부채 ————108.27 M108.18 M 순부채 ————-212.3 M-288.01 M

뉴스

Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results - Rhythm Pharmaceutical

Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2026 Earnings Call Transcript

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue Estimates

Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth

Analysts Estimate Rhythm Pharmaceuticals, Inc. (RYTM) to Report a Decline in Earnings: What to Look Out for

Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 12.6% Jump Turn into More Strength?

Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Approval of IMCIVREE for Acquired Hypothalamic Obesity - Slideshow (NASDAQ:RYTM) 2026-03-24

Rhythm Surges On A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat'

Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Approval of IMCIVREE for Acquired Hypothalamic Obesity Transcript

Tracking Baker Brothers Portfolio – Q4 2025 Update (NASDAQ:INCY)

Rhythm Pharmaceuticals Misses The Beat In Obesity, But There's A Caveat